Bridgeway Capital Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Bridgeway Capital Management’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3,492	Closed	-$381K	–	1415
2018 Q4	$381K	Buy	3,492 +1,533	+78%	+$307K	0.01%	1077
2018 Q3	$431K	Buy	+1,959	New	+$4.7M	﹤0.01%	1181
2015 Q2	–	Sell	-45	Closed	-$42K	–	1537
2015 Q1	$42K	Hold	45	–	–	﹤0.01%	1461
2014 Q4	$46K	Hold	45	–	–	﹤0.01%	1435
2014 Q3	$46K	Hold	45	–	–	﹤0.01%	1459
2014 Q2	$86K	Buy	45 +27	+150%	+$53.4K	﹤0.01%	1405
2014 Q1	$38K	Hold	18	–	–	﹤0.01%	1407
2013 Q4	$41K	Hold	18	–	–	﹤0.01%	1379
2013 Q3	$50K	Hold	18	–	–	﹤0.01%	1411
2013 Q2	$162K	Buy	+18	New	+$139K	0.01%	1305

Other funds holding ONCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bridgeway Capital Management's ONCT Position: Q1 2019 in Review

Bridgeway Capital Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2019, closing a stake of 3,492 shares — an estimated $381K sold.

Bridgeway Capital Management first reported a position in ONCT in Q2 2013 and held it in 10 quarters. The position peaked at $431K in Q3 2018. 35 funds tracked by Wall St. Rank hold ONCT as of Q1 2019.

Bridgeway Capital Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Bridgeway Capital Management sold 3,492 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $381K.
Bridgeway Capital Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 10 quarters.
Bridgeway Capital Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $431K in Q3 2018.
35 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Bridgeway Capital Management's 13F filing for Q1 2019, filed 15 May 2019.